Archives for March 28, 2014

Dispatches from DIA Euromeeting

INN debate: IFPMA pushes for biosimilar label changes

IFPMA will advocate for all biologics to have a qualifier added to their names at the WHO’s INN Consultation on April 8, the biologics giant Amgen has told BioPharma-Reporter.com.

Baxter spin-off to focus on biosimilars and haematology growth

The spin-off of Baxter’s biopharmaceutical business will be driven by haematology and biosimilar growth opportunities, the company says.

Grace says silica-packed mAb capture columns can cut costs 60%

WR Grace has launched a new column technology that it claims can reduce mAb manufacturers’ downstream purification costs by up to 60%.

Cytovance extends mAb manufacturing agreement with Precision Biologics

CMO Cytovance Biologics is extending its manufacturing agreement with Precision Biologics to advance clinical trials with its leading monoclonal antibody candidate, which is being developed as a therapeutic candidate for pancreatic and colorectal cancers.  

dispatches from interphex

Integrating single-use into existing facilities still a challenge, says ASI

Integrating single-use systems into existing facilities is still a challenge to the adoption of such technologies, according to ASI.